Bone status of children aged 5-8 years, treated with dexamethasone for chronic lung disease of prematurity

Arch Dis Child Fetal Neonatal Ed. 2008 May;93(3):F222-4. doi: 10.1136/adc.2006.110874. Epub 2007 Aug 17.

Abstract

Background: It is not known whether treatment with dexamethasone in the neonatal period may lead to reduced bone mineral density in childhood.

Methods: Anthropometric and bone densitometry measurements were taken of children aged 5-8 years who had chronic lung disease (CLD) in the neonatal period (n = 22). 15 of these children were treated with dexamethasone. A control group consisted of children born preterm who did not develop CLD (n = 29).

Results: Total body bone mineral content and bone mineral apparent density of the lumbar spine were lower in children whose CLD was treated with dexamethasone in the neonatal period, compared with the preterm controls.

Conclusion: Dexamethasone treatment in the neonatal period appears to cause impairment of mineralisation which persists into childhood.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bone Density / drug effects*
  • Case-Control Studies
  • Child
  • Child, Preschool
  • Chronic Disease
  • Dexamethasone / adverse effects*
  • Female
  • Glucocorticoids / adverse effects*
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Infant, Premature, Diseases / drug therapy*
  • Lung Diseases / drug therapy*
  • Male
  • Pilot Projects

Substances

  • Glucocorticoids
  • Dexamethasone